The BioInsights Podcast
The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.
The BioInsights Podcast
Happy medium: considerations in scaling cell culture media strategies
•
BioInsights
•
Season 2
•
Episode 10
While attractive from an initial cost perspective, performing early development in a cell culture substrate that does not match a therapy’s final manufacturing platform can have critical implications on development timelines. In this podcast, Charlotte Barker, Editor, BioInsights, speaks to Dalip Sethi, Director of Scientific Affairs, Terumo BCT, about best practices for scaling up cell culture substrate.
Cell culture media is a big consideration for therapy developers— does Terumo Blood and Cell Technologies (BCT) have a media offering?
What are the media-related considerations when you are using a closed automated bioreactor system—including the in-process analytical components?
That’s very interesting to note… Not the ‘first line’ issues that you mentioned earlier, but certainly something that can affect therapy development timelines. What does Terumo BCT see as a mitigation strategy?